Drug Trial Radar · NCT00861926
Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2)
Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,714
Actual
Start
Mar 20, 2009
Primary completion
Dec 7, 2010
Study completion Dec 7, 2010
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Mar 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary objective: The primary objective of the study was to compare the efficacy of Maintenance and Reliever Therapy (MART) with Foster® 100/6 μg (one inhalation bid) plus additional inhalations as needed, with the standard treatment of Foster® 100/6 μg (one inhalation bid) plus salbutamol 100 μg (Ventolin ®) additional inhalations as needed in not fully controlled asthmatic patients. Secondary objectives: The secondary objectives of the study were: * to evaluate the effect of treatments on lung function parameters and on other clinical outcome measures, and * to assess the safety and the tolerability of Foster® as MART.
Conditions
- Asthma
Interventions
SalbutamolDrug
Administered via a pressurized metered-dose inhaler
Beclomethasone dipropionate + FormoterolDrug
Administered via a pressurized metered-dose inhaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Severe Asthma ExacerbationTime frame: From First IMP dose to week 48 (EOT)
- Cumulative Number of Patients With Severe Asthma Exacerbation by Inter-visit (Measured in Weeks)Time frame: From First dose to end of each interval: 0-4, 4-12, 12-24, 24-36, 36-48 weeks
Locations
206 sites in 14 countries. Site status is shown where the registry gives one.
Chiesi Site No 103
Burgas, Bulgaria
Chiesi Site No 107
Pleven, Bulgaria
Chiesi Site No 105
Plovdiv, Bulgaria
Chiesi Site No 111
Plovdiv, Bulgaria
Chiesi Site No 115
Plovdiv, Bulgaria
Chiesi Site No 102
Rousse, Bulgaria
Chiesi Site No 104
Sofia, Bulgaria
Chiesi Site No 108
Sofia, Bulgaria
Chiesi Site No 109
Sofia, Bulgaria
Chiesi Site No 110
Sofia, Bulgaria
Chiesi Site No 113
Sofia, Bulgaria
Chiesi Site No 117
Sofia, Bulgaria
Chiesi Site No 106
Stara Zagora, Bulgaria
Chiesi Site No 116
Troyan Municipality, Bulgaria
Chiesi Site No 0101
Varna, Bulgaria
Chiesi Site No 112
Veliko Tarnovo, Bulgaria
Chiesi Site No 305
Osijek, Croatia
Chiesi Site No 304
Rijeka, Croatia
Chiesi Site No 306
Zadar, Croatia
Chiesi Site No 301
Zagreb, Croatia
Chiesi Site No 302
Zagreb, Croatia
Chiesi Site No 307
Zagreb, Croatia
Chiesi Site No 201
Beroun, Czechia
Chiesi Site No 206
Brno, Czechia
Chiesi Site No 207
Brno, Czechia
Chiesi Site No 202
Prague, Czechia
Chiesi Site No 203
Prague, Czechia
Chiesi Site No 204
Prague, Czechia
Chiesi Site No 205
Prague, Czechia
Chiesi Site No 208
Prague, Czechia
Chiesi Site No 428
Angoulême, France
Chiesi Site No 421
Castelnau-le-Lez, France
Chiesi Site No 434
Chauny, France
Chiesi Site No 403
Dijon, France
Chiesi Site No 408
Hyères, France
Chiesi Site No 424
Marmande, France
Chiesi Site No 410
Marseille, France
Chiesi Site No 436
Marseille, France
Chiesi Site No 418
Montpellier, France
Chiesi Site No 417
Nice, France
Showing 40 of 206 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.